Calibrating Models in Economic Evaluation
暂无分享,去创建一个
[1] J. Karnon,et al. Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). , 2009, Journal of evaluation in clinical practice.
[2] M K Campbell,et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.
[3] J. Forbes,et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.
[4] M. Jit,et al. Estimating Progression Rates for Human Papillomavirus Infection From Epidemiological Data , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[5] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[6] Richard G. White,et al. Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.
[7] Nicky J Welton,et al. Multiparameter evidence synthesis in epidemiology and medical decision-making , 2008, Journal of health services research & policy.
[8] J. Karnon,et al. Cost-utility analysis of screening high-risk groups for anal cancer. , 2008, Journal of public health.
[9] J. Karnon,et al. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. , 2008, Health technology assessment.
[10] Jonathan Karnon,et al. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective , 2008, The European Journal of Health Economics.
[11] Milton C. Weinstein,et al. Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.
[12] Jonathan Karnon,et al. A Hybrid Cohort Individual Sampling Natural History Model of Age-Related Macular Degeneration: Assessing the Cost-Effectiveness of Screening Using Probabilistic Calibration , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.
[13] J. Karnon. Aromatase Inhibitors in Breast Cancer , 2012, PharmacoEconomics.
[14] M Sculpher,et al. Health Technology Assessment: Development and Future , 2009 .
[15] Karen M Kuntz,et al. Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.
[16] Tejal K. Gandhi,et al. A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions , 2007 .
[17] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.